TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
1-Year Return
18.15%
This Quarter Return
+4.56%
1 Year Return
+18.15%
3 Year Return
+62.34%
5 Year Return
+140.22%
10 Year Return
+499.57%
AUM
$2.67B
AUM Growth
+$41.2M
(+1.6%)
Cap. Flow
-$9.43M
Cap. Flow
% of AUM
-0.35%
Top 10 Holdings %
Top 10 Hldgs %
35.39%
Holding
233
New
11
Increased
50
Reduced
32
Closed
29
Top Buys
| 1 |
AbbVie
ABBV
|
$29.9M |
| 2 |
Illumina
ILMN
|
$20.5M |
| 3 |
Steris
STE
|
$20.4M |
| 4 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$18.9M |
| 5 |
Humana
HUM
|
$15.5M |
Top Sells
| 1 |
Johnson & Johnson
JNJ
|
$42.2M |
| 2 |
Thermo Fisher Scientific
TMO
|
$33.8M |
| 3 |
UnitedHealth
UNH
|
$29.4M |
| 4 |
IMMU
Immunomedics Inc
IMMU
|
$23.3M |
| 5 |
Vertex Pharmaceuticals
VRTX
|
$20.7M |
Sector Composition
| 1 | Healthcare | 95.21% |
| 2 | Real Estate | 2.74% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Eli Lilly
LLY
$652B
| $26.3M | 0.99% |
177,637
-29,200
| -14% | -$4.32M |
|
27
Zimmer Biomet
ZBH
$20.9B
| $26.1M | 0.98% |
197,695
+100,202
| +103% | +$13.2M |
|
28
Alnylam Pharmaceuticals
ALNY
$59.2B
| $25.5M | 0.95% |
174,894
+49,027
| +39% | +$7.14M |
|
29
BioMarin Pharmaceuticals
BMRN
$11.1B
| $24.8M | 0.93% |
325,822
+80,460
| +33% | +$6.12M |
|
30
Edwards Lifesciences
EW
$47.5B
| $23.2M | 0.87% |
291,155
+89,009
| +44% | +$7.1M |
|
31
CVS Health
CVS
$93.6B
| $22.7M | 0.85% |
388,263
-331,357
| -46% | -$19.4M |
|
|
32
Steris
STE
$24.2B
| $22.3M | 0.84% |
126,779
+115,561
| +1,030% | +$20.4M |
|
33
Waters Corp
WAT
$18.2B
| $21.4M | 0.8% |
109,510
+72,326
| +195% | +$14.2M |
|
34
Ascendis Pharma
ASND
$12.5B
| $19.4M | 0.73% |
125,746
+68,264
| +119% | +$10.5M |
|
35
Sanofi
SNY
$113B
| $19.2M | 0.72% |
381,920
+54,553
| +17% | +$2.74M |
|
|
IMMU
36
DELISTED
Immunomedics Inc
IMMU
| $19M | 0.71% |
223,336
-273,767
| -55% | -$23.3M |
|
37
AstraZeneca
AZN
$253B
| $18.9M | 0.71% |
344,333
+109,535
| +47% | +$6M |
|
38
Dentsply Sirona
XRAY
$2.92B
| $17.9M | 0.67% |
408,473
+247,186
| +153% | +$10.8M |
|
39
Intuitive Surgical
ISRG
$167B
| $17.8M | 0.67% |
75,207
-24,810
| -25% | -$5.87M |
|
40
ResMed
RMD
$40.6B
| $16.6M | 0.62% |
97,069
+79,238
| +444% | +$13.6M |
|
41
argenx
ARGX
$45.9B
| $16.2M | 0.61% |
61,687
+16,710
| +37% | +$4.39M |
|
42
McKesson
MCK
$85.5B
| $16M | 0.6% |
107,537
| – | – |
|
|
BPMC
43
DELISTED
Blueprint Medicines
BPMC
| $15.8M | 0.59% |
170,018
+51,762
| +44% | +$4.8M |
|
44
Viatris
VTRS
$12.2B
| $15M | 0.56% |
1,010,754
| – | – |
|
45
Danaher
DHR
$143B
| $14.5M | 0.55% |
76,216
-103,533
| -58% | -$19.8M |
|
46
Incyte
INCY
$16.9B
| $13.7M | 0.51% |
152,605
-172,448
| -53% | -$15.5M |
|
47
Idexx Laboratories
IDXX
$51.4B
| $13.7M | 0.51% |
34,814
-2,200
| -6% | -$865K |
|
48
Labcorp
LH
$23.2B
| $13.2M | 0.49% |
81,483
+26,483
| +48% | +$4.28M |
|
49
Novartis
NVS
$251B
| $13.2M | 0.49% |
151,525
-19,483
| -11% | -$1.69M |
|
50
Guardant Health
GH
$7.5B
| $13.2M | 0.49% |
117,852
+36,430
| +45% | +$4.07M |
|